The global hemostasis and tissue sealing agents market size is expected to reach USD 10.34 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.7% during the forecast period. The agents have gained popularity over time due to their ability to prevent blood loss. Rapid growth of minimal invasive technology and demand for faster recovery by patients is expected to promote market growth over the forecast period.
According
to the Centers for Disease Control and Prevention (CDC), approximately 150
million of American population is currently suffering from at least one chronic
condition, which leads to surgeries and even mortality at times. An estimate
over the rising incidence was made by the CDC, which concluded that over 48% of
the entire American population is expected to suffer by chronic condition.
The
hemostasis and tissue sealing agents market is expected to witness lucrative
growth over the next seven years owing to, an increase in demand supported by
rising surgery volumes. Growth in geriatric population and prevalence of
chronic conditions are the impact rendering drivers for this industry.
Full Research Report On Hemostasis & Tissue Sealing Agents Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/hemostasis-tissue-sealing-agents-market
Further key
findings from the report suggest:
- The hemostats
market is expected to expand at a CAGR of over 8.7% over the forecast
period owing to the rise in global volume of surgeries and applicability
of the product across a variety of surgeries to avoid occurrence of
hypovolemic shock, thrombocytopenia, blood transfusions, and
post-operative complications
- Flowable
hemostats are a combination of active and mechanical agents. They function
by blocking blood flow and also converting fibrinogen into fibrin for
coagulation. This segment is expected to witness a lucrative CAGR of over
10.0% from 2018 to 2026
- Some key
players operating in the hemostasis and tissue sealing agents market
include Johnson & Johnson; CryoLife Inc.; Pfizer; C R Bard; B Braun;
Covidien; and Smith & Nephew. Market participants are involved in
technological advancements to ensure sustainability and regional presence
- For instance,
in March 2015, Ethicon announced higher efficiency of EVARREST fibrin
sealant patch as compared to its substitute, TachoSil patch (Baxter).
Further study would be conducted at the St. Vincent Heart Centre of
Indiana to understand added advantages that the product can offer.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/hemostasis-tissue-sealing-agents-market/request/rs1
Grand View Research has
segmented the global hemostasis and tissue sealing agents market on the basis
of product and region:
Hemostasis and
Tissue Sealing Agents Product Outlook (Revenue, USD Million, 2015 - 2026)
- Topical Hemostat
- Adhesive & tissue sealant
Hemostasis and
Tissue Sealing Agents Regional Outlook (Revenue, USD Million, 2015 - 2026)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- China
- Japan
- India
- Thailand
- South Korea
- Latin America
- Mexico
- Brazil
- Argentina
- Colombia
- MEA
- South Africa
- Saudi Arabia
- UAE
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment